AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with